Synairgen has temporarily halted the ACTIV-2 Phase III clinical trial of its therapy SNG001 for Covid-19.
The latest move comes after the requirement to modify the trial design due to the emergence of the SARS-CoV-2 virus’ Omicron variant.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Furthermore, the team of the US National Institutes of Health (NIH) ACTIV-2 trial asked the company to provisionally halt activities to ready clinical supplies for ACTIV-2 Phase III until the timeline for the activation of SNG001 in the study is clarified.
Synairgen is awaiting results from the Phase II part of the US NIH ACTIV-2 trial conducted on Covid-19 patients in the at-home setting. The data is anticipated in the middle of this year.
An inhaled formulation, SNG001 contains the broad-spectrum antiviral protein interferon beta.
According to data from in vitro studies carried out at Viroclinics-DDL in the Netherlands, SNG001 demonstrated to possess potent antiviral activity against Delta and Omicron viral variants at doses that are easily achievable after inhaled administration of interferon-beta.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAs reported in February this year, the company is assessing the top-line as well full dataset from the Phase III SPRINTER clinical trial to attain a better understanding of the results.
Synairgen will report the findings of this assessment soon in compliance with regulatory requirements.
The SPRINTER trial showed a favourable trend in preventing progression to severe disease and morality with a 36% decline in the pre-defined per-protocol population.
Synairgen and its clinical advisors believe that the data warrants additional analysis in a platform trial, which the company is currently studying.
Synairgen reported in February this year that the international Phase III trial of SNG001 in Covid-19 patients admitted to the hospital failed to meet the primary or secondary efficacy endpoints.
